Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab - Test2 - elhamkhani - TriplyDB

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

http://www.wikidata.org/entity/Q29620596

about

Radiotherapy combination opportunities leveraging immunity for the next oncology practice The European Organization for Research and Treatment of Cancer perspective on designing clinical trials with immune therapeutics Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting The role of pembrolizumab in the treatment of advanced non-small cell lung cancer Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy Emerging molecular classifications and therapeutic implications for gastric cancer Clinical utility of nivolumab in the treatment of advanced melanoma Cancer immunotherapy: the beginning of the end of cancer?Cytokine-Induced Modulation of Colorectal Cancer The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines Pathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell Vaccination Advances in immunotherapy for melanoma PD-1/PD-L1 blockade in cancer treatment: perspectives and issues Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced Melanoma Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma New therapeutic strategies for BRAF mutant colorectal cancers Medical management of malignant melanoma Current status of immunotherapy Evidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies Immune checkpoint inhibitors: therapeutic advances in melanoma Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations Immune cell interplay in colorectal cancer prognosis New developments in the management of advanced melanoma - role of pembrolizumab Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy Antagonists of PD-1 and PD-L1 in Cancer Treatment The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients Nivolumab in the treatment of malignant melanoma: review of the literature Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors Predictive biomarkers in precision medicine and drug development against lung cancer Universes collide: combining immunotherapy with targeted therapy for cancer The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity

P2860

Q26738443-4C663350-48B0-4D43-AFF6-38E5C2FF015B Q26738677-BA31701E-1ECC-4488-8131-52DCE1B48340 Q26742012-CEF264A9-F375-4302-989F-F32355800600 Q26744076-38762493-C658-467D-B21C-111DB1E2303D Q26745444-5EFD7016-3134-40DB-B56E-9013C1E967AE Q26745516-A7BA6912-5E9D-46B4-9AC3-304847487652 Q26745525-870D794F-B47D-4B7C-983D-2A08683DD793 Q26751268-8F51BB16-1DB3-4D9C-8973-88577E327A98 Q26752277-51A7C505-82DC-40E6-ABCA-D08F0820A606 Q26752374-4C499C5C-C77E-4D8C-832D-7C6909984262 Q26764792-7CD61CD3-EF87-4F21-BB77-B5E7F6307666 Q26765345-DC9C9074-85A6-4682-BF54-060C988D6359 Q26768558-4B1582BB-DEC8-4E8F-BDD3-D9F7ECDB1EB2 Q26768641-8B69F4E1-A5D9-4D38-B59F-B32227B26C36 Q26769884-D4D60A0F-3D9A-4718-88DA-4037E7257E9A Q26770492-AE3CF7F8-6F79-4BDB-A04A-1C7B98EAA34F Q26771119-E78AC210-B479-4B1F-AD77-7B0E2CC643BA Q26772015-85FA1817-353B-4A93-A221-35E505181455 Q26772277-D23B937C-7E99-43B5-820B-7FEB3FBAF57D Q26773302-8FCEAEDA-13AF-4169-A87F-26226CB34270 Q26773314-6C68E278-D27C-4065-83E1-77883876386B Q26775030-B304A3AE-0EB1-4AD6-B4B8-0D7D148CFE9A Q26775034-9709E9E3-C0C6-44CA-9062-9CD5C82D0567 Q26775591-8D028BB9-FA09-44CB-B21E-8023EA68DFA0 Q26776394-6EFE1548-0C82-44EB-890D-A697BF23C709 Q26777563-23C2085D-48B4-47C7-BFBC-DB92BA95841F Q26778793-2FCBA13B-2946-431A-BB26-07EEAA51CE08 Q26781038-2E7653EC-6044-43AE-B221-5C22D29E3C63 Q26781453-7835DBAB-ACCE-4544-B4D8-9CB80E57E2B0 Q26781931-C6C12F3D-3EAE-4619-AC36-EE3BCA7C61BD Q26795509-3462F259-6890-4B3B-8564-78406E233274 Q26796309-F853F474-6060-4372-AA54-0D603CE24309 Q26796311-8FDC6FAE-103B-43EF-9921-2D4D80FACD6E Q26797478-071ABFD1-2368-4C34-B8F1-ADC234699241 Q26798330-744A9B95-A1A5-42B2-9892-98FD01E0FB8E Q26798404-3F67E69B-F274-4A0B-B5E9-86C51C0EF63A Q26799812-CDC1772E-C486-459C-B773-7BE27718CD46 Q26824536-FAC01094-2171-43E2-A2D9-CCA95AD911B9 Q26825316-5DF28863-2591-4820-A81A-183C2EBD4D74 Q26829847-A7B754CD-7ADC-478E-92F8-2241C99B669D

P2860

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

http://www.wikidata.org/entity/Q29620596

description

2014 nî lūn-bûn

@nan

2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@ast

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@en

type

label

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@ast

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@en

prefLabel

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@ast

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@en

P1433

Q29620596-67B5352F-0589-498F-A5A1-DCBA33C9F1AF

P1476

Q29620596-CDEC9DF3-616B-4650-8FC8-54FF69C5500B

P2093

Q29620596-06A80A1E-FD2C-4284-9019-B3C16E9E473C

Q29620596-28B0B4BF-24CD-4285-AED1-881E6C49D751

Q29620596-7084587B-CA05-416B-A41F-913A159725A0

Q29620596-74AA15A6-84F5-48CE-87DE-2D370CE97C74

Q29620596-78979290-645F-4C09-AE6A-F960A797430F

Q29620596-83BF1C7E-6D81-46A2-BDD9-CF6E157BC277

Q29620596-8A84D09E-AA53-43E7-830C-B2841A1BF07B

Q29620596-8C68C22F-C9AB-4B86-B180-0682E79B1AF1

Q29620596-9BD23804-D666-46CD-A5FC-D2403BAECB5F

Q29620596-AF9D4DF8-A046-4B41-92F3-76C235516E38

P2860

Q29620596-031A3441-6524-4980-8039-E374ED899206

Q29620596-081C6A7B-52F3-4A2D-9F48-3A5129E6BD84

Q29620596-0984ED64-E417-4035-9C7F-1D52BA49BE9A

Q29620596-0CB9226E-66A7-45F3-8383-9B86B0FD8A1E

Q29620596-118605F5-EB57-4BBF-A9D3-700A71B407BD

Q29620596-14A76A26-2402-4117-995B-B0322A5E33B4

Q29620596-195121D3-0FDA-4693-BCEB-CD2D51F2B82E

Q29620596-21A69AF4-F630-4FC2-8F84-3BF2802F7E1D

Q29620596-32BEC12D-438D-41C7-8CEB-0D05D750B7ED

Q29620596-3F540A4F-36D9-4820-8C5A-13B878D8F6EB

P304

Q29620596-5C5BD4B7-825E-4E98-974E-884FA2C72DA8

P31

Q29620596-32272F90-A285-4876-819A-0BC165B11779

P3181

Q29620596-E6D646EE-1CA1-49BE-B97B-11AEFD4D33DF

P356

Q29620596-454DC3F2-F8F1-499F-813F-E0F090437A0B

P407

Q29620596-AB3F6A41-1DA8-44DD-9A38-B75880A4D0DC

P433

Q29620596-86FF8341-6C9E-4CDD-9292-497E92F5C264

P478

Q29620596-D34DD7F2-36A9-42FC-B34B-5EA36DE07712

P577

Q29620596-19C7924B-5ABE-494C-BD86-BC43F8FD3982

P698

Q29620596-680F3B98-73C4-4189-A07C-88836C7C3701

P932

Q29620596-C3627DEC-951B-42EF-B286-A7FE1C0045CC

P3181

P356

JCO.2013.53.0105

P1433

Journal of Clinical Oncology

P1476

Survival, durable tumor remiss ...... d melanoma receiving nivolumab

@en

P2093

Atkins MB

http://www.w3.org/2001/XMLSchema#string

Brahmer JR

http://www.w3.org/2001/XMLSchema#string

Carvajal RD

http://www.w3.org/2001/XMLSchema#string

Gupta A

http://www.w3.org/2001/XMLSchema#string

Hodi FS

http://www.w3.org/2001/XMLSchema#string

Kluger HM

http://www.w3.org/2001/XMLSchema#string

Kollia GD

http://www.w3.org/2001/XMLSchema#string

Lawrence DP

http://www.w3.org/2001/XMLSchema#string

Leming PD

http://www.w3.org/2001/XMLSchema#string

Lipson EJ

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

The blockade of immune checkpoints in cancer immunotherapy

P304

1020-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1222146

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2013.53.0105

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24590637

http://www.w3.org/2001/XMLSchema#string

P932

4811023

http://www.w3.org/2001/XMLSchema#string